All In Biotech

Drug Trial Radar · NCT01926782

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia

Last checked: Nov 20, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 803 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

803

Actual

Start

Sep 2013

Primary completion

Sep 2014

Study completion Apr 2015

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Aug 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy, long-term safety, and tolerability of alirocumab 300 mg every 4 weeks (Q4W), in comparison with placebo, as well as its potential as a starting regimen. The dose regimen of 75 mg every 2 weeks (Q2W), as used in other studies, was added as a calibrator.

Conditions

  • Hypercholesterolemia

Interventions

  • Placebo (for alirocumab)Drug

    Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.

  • AlirocumabDrug

    Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.

  • StatinDrug

    Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT AnalysisTime frame: From Baseline to Week 24
  2. Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)Time frame: From Baseline to Week 24

Locations

83 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Chandler, Arizona

  • Site not named

    Goodyear, Arizona

  • Site not named

    Carmichael, California

  • Site not named

    Fresno, California

  • Site not named

    West Hills, California

  • Site not named

    Wildomar, California

  • Site not named

    Colorado Springs, Colorado

  • Site not named

    Golden, Colorado

  • Site not named

    Boynton Beach, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Safety Harbor, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Meridian, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Gurnee, Illinois

  • Site not named

    Evansville, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Kansas City, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Monroe, Louisiana

  • Site not named

    Auburn, Maine

  • Site not named

    Methuen, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Rochester, New York

  • Site not named

    Farmville, North Carolina

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Wilson, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Wyomissing, Pennsylvania

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.